Annals of hepatology最新文献

{"title":"A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study","authors":"Jeffrey V. Lazarus ,&nbsp;William Alazawi ,&nbsp;Ron Basuroy ,&nbsp;Laurent Castera ,&nbsp;Dmitry Estulin ,&nbsp;Yiannoula Koulla ,&nbsp;Preethy Prasad ,&nbsp;Manuel Romero-Gomez ,&nbsp;Hirokazu Takahashi ,&nbsp;Vincent Wai-Sun Wong ,&nbsp;Jörn M. Schattenberg","doi":"10.1016/j.aohep.2024.101741","DOIUrl":"10.1016/j.aohep.2024.101741","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Patients increasingly use social media to share and access health-related information and experiences. This study employed social media listening to gain patient-centric insights into metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD).</div></div><div><h3>Materials and Method</h3><div>Publicly available social media data was collected between November 4th, 2020, and November 4th, 2022, about MASLD from eight countries: Brazil, China, France, Germany, Japan, South Korea, Spain, and the United Kingdom. The analysis involved capturing patient conversations on their journey stages (causes-risk factors, symptoms, diagnosis, and treatment), unmet needs, and impact on patient's quality of life (QoL) from various social media platforms to gain insights associated with MASLD.</div></div><div><h3>Results</h3><div>A total of 1600 patient-centric posts were analyzed. The patient journey was the most prevalent topic (92 %) mentioned, followed by comorbidities (38 %) and interactions with HCPs (26 %, health care professionals). Key causes discussed included unhealthy diet (39 %) and overweight/obese (32 %), while the most mentioned symptoms were fatigue (20 %) and pain or abdominal discomfort (20 %). Ultrasound (n=170/553, 31 %) was the most used diagnosis, followed by blood tests (n=130/553, 24 %) and liver function tests (n=91/553, 16 %). Lifestyle management techniques were mainly the standard of care, followed by treatment (n=270/1061, 25 %) and follow-ups with HCPs (n=133/1061, 13 %). Over half (54 %) of the QoL discussion (n=104/192) focused on patients’ comorbidities, and 27 % on disease severity, indicating that having MASLD in moderate to severe form with comorbidities significantly affects patients’ quality of life. An emotional analysis revealed that patients were worried and frustrated about their condition but were also hopeful and determined to improve their health. Nearly 38 % of the posts mentioned that patients were emotionally affected by negative feelings, especially those with multiple comorbidities. Lack of access to knowledgeable HCPs and treatment options were the most frequently discussed unmet needs.</div></div><div><h3>Conclusions</h3><div>This analysis of NAFLD patient experiences introduces a unique approach for deriving insights into patients' experiences and their impact on QoL. These insights have the potential to complement conventional methods and foster patient-centric research.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101741"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142778866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial","authors":"Do Seon Song ,&nbsp;Jin Mo Yang ,&nbsp;Young Kul Jung ,&nbsp;Hyung Joon Yim ,&nbsp;Hee Yeon Kim ,&nbsp;Chang Wook Kim ,&nbsp;Soon Sun Kim ,&nbsp;Jae Youn Cheong ,&nbsp;Hae Lim Lee ,&nbsp;Sung Won Lee ,&nbsp;Jeong-Ju Yoo ,&nbsp;Sang Gyune Kim ,&nbsp;Young Seok Kim","doi":"10.1016/j.aohep.2024.101749","DOIUrl":"10.1016/j.aohep.2024.101749","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>The short-term mortality of severe alcoholic-associated hepatitis (SAH) is high, but there are no effective treatments to improve short-term mortality other than corticosteroids. This study investigated the effects of adding rifaximin to standard treatment in patients with SAH.</div></div><div><h3>Material and Methods</h3><div>In this randomized controlled open-label trial, patients with SAH (Maddrey's discriminant function≥32) were randomized to the rifaximin or control group. Patients were simultaneously treated with corticosteroid or pentoxifylline as standard treatment for 4 weeks. Randomization was stratified by SAH treatment.</div></div><div><h3>Results</h3><div>A total of 50 patients were enrolled in this study (29 in the control group and 21 in the rifaximin group). The mean Model for End-stage Liver Disease (MELD) scores were 24.4 and 27.5 in the control and rifaximin groups, respectively (<em>P</em> = 0.106). There were no significant differences in 6-month Liver Transplantation (LT)-free survival rate between the two groups (<em>P</em> = 0.502). When stratified by SAH treatment, there was no significant difference in 6-month LT-free survival rate between the control and rifaximin treatment groups (<em>P</em> = 0.186 in the corticosteroid group and <em>P</em> = 0.548 in the pentoxifylline group). There were no significant differences in the occurrence of liver-related complications between the two groups (all <em>P</em>s&gt;0.05). The MELD score was the only independent factor for 6-month LT-free survival (hazard ratio 1.188, 95 % confidence interval 1.094-1.289, <em>P</em>&lt;0.001), and rifaximin was not.</div></div><div><h3>Conclusions</h3><div>In patients with SAH, adding rifaximin to corticosteroid or pentoxifylline had no survival benefit and no preventive effect on the development of liver-related complications. The MELD score was the only significant factor for short-term mortality.</div></div><div><h3>Clinical trial registration</h3><div>The study was registered on <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (number: <span><span>NCT02485106</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101749"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentially expressed genes in Huh7 cells during co-culture with LX2 cells demonstrating dynamics of intercellular communication","authors":"Tania G. Heredia-Torres,&nbsp;Veronica Alvarado-Martínez,&nbsp;Ana R. Rincón-Sánchez,&nbsp;Sonia A. Lozano-Sepúlveda,&nbsp;Kame A. Galán-Huerta,&nbsp;Daniel Arellanos-Soto,&nbsp;Ana M. Rivas-Estilla","doi":"10.1016/j.aohep.2024.101746","DOIUrl":"10.1016/j.aohep.2024.101746","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101746"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein”","authors":"Liang Zhao,&nbsp;Husaiyin Erhati,&nbsp;Sailai Yalikun","doi":"10.1016/j.aohep.2024.101760","DOIUrl":"10.1016/j.aohep.2024.101760","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101760"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience","authors":"Thanikan Sukaram ,&nbsp;Soe Thiha Maung ,&nbsp;Yuda Chongpison ,&nbsp;Tassanan Jaihan ,&nbsp;Chonlada Phathong ,&nbsp;Roongruedee Chaiteerakij","doi":"10.1016/j.aohep.2024.101753","DOIUrl":"10.1016/j.aohep.2024.101753","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>FibroTouch® has shown efficacy in staging hepatic fibrosis in patients with chronic viral hepatitis B, but its performance in assessing liver steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients remains understudied. We aimed to evaluate the diagnostic performance of FibroTouch® in assessing steatosis and fibrosis in the MASLD population.</div></div><div><h3>Materials and Methods</h3><div>Liver stiffness measurements and steatosis were assessed using FibroTouch® and FibroScan®, with FibroScan® as the reference standard. Pearson's correlation test evaluated correlations, and kappa statistics determined agreement between the two methods. Optimal cut-off values of FibroTouch® for predicting hepatic steatosis and fibrosis stages were determined through ROC curve analysis with the Youden index method.</div></div><div><h3>Results</h3><div>Strong correlations were observed between FibroTouch® UAP and FibroScan® CAP (rho=0.74) and LSM values (rho=0.87) (<em>p</em> &lt; 0.001 for both) in a total of 380 patients. The mean CAP value for the entire cohort was 285 ± 51 dB/m, and the median LSM for the cohort was 5 .3kPa. The optimal FibroTouch® UAP cutoffs were 229 dB/m for S0 vs. S1, 267 dB/m for S1 vs. S2, and 294 dB/m for S2 vs. S3. For FibroTouch® LSM, the optimal cutoffs were 6.0 kPa for F0-F1 vs. F2, 7.9 kPa for F2 vs. F3, and 10.6 kPa for F3 vs. F4. Moreover, FibroTouch® effectively assessed hepatic steatosis and fibrosis in patients with different BMIs.</div></div><div><h3>Conclusions</h3><div>FibroTouch® proved valuable in assessing hepatic steatosis and liver fibrosis staging in MASLD patients, enhancing its applicability in various clinical settings as a suitable and convenient option for MASLD patients.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101753"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142798665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing liver fibrosis in chronic liver disease: Comparison of diffusion-weighted MR elastography and two-dimensional shear-wave elastography using histopathologic assessment as the reference standard","authors":"Li Yang ,&nbsp;Guofeng Zhou ,&nbsp;Liheng Liu ,&nbsp;Shengxiang Rao ,&nbsp;Wentao Wang ,&nbsp;Kaipu Jin ,&nbsp;Caixia Fu ,&nbsp;Mengsu Zeng ,&nbsp;Ying Ding","doi":"10.1016/j.aohep.2024.101743","DOIUrl":"10.1016/j.aohep.2024.101743","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Liver stiffness measurement (LSM) by two-dimensional shear-wave elastography (2D SWE) is a well-established method for assessing hepatic fibrosis. Diffusion-weighted imaging (DWI) can be converted into virtual shear modulus (µ_Diff) to estimate liver elasticity. The purpose of this study was to correlate and compare the diagnostic performance of DWI-based virtual elastography and 2D SWE for staging hepatic fibrosis in patients with chronic liver disease, using histopathologic assessment as the reference standard.</div></div><div><h3>Patients and Methods</h3><div>This retrospective study included 111 patients who underwent preoperative multiple b-value DWI and 2D SWE. The µ_Diff was calculated using DWI acquisition with b-values of 200 and 1,500 /mm², and LSM was obtained by 2D SWE. Correlation between µ_Diff and LSM was assessed, as well as the correlation between these noninvasive methods and histologic fibrosis stages. The diagnostic efficacy of µ_Diff and LSM for staging liver fibrosis was compared with receiver operating characteristic (ROC) curve analysis.</div></div><div><h3>Results</h3><div>There was a significant positive correlation between µ_Diff and LSM (rho= 0.48, <em>P</em> &lt; 0.001). µ_Diff (rho= 0.54, <em>P</em> &lt; 0.001) and LSM (rho= 0.76, <em>P</em> &lt; 0.001) were positively correlated with liver fibrosis stages. Areas under the curves (AUCs) of µ_Diff and LSM, respectively, were 0.81 and 0.90 for significant fibrosis, 0.89 and 0.98 for advanced fibrosis, and 0.77 and 0.91 for cirrhosis. The AUCs of 2D SWE for diagnosing advanced fibrosis and cirrhosis were significantly higher than those of µ_Diff (<em>P</em> &lt; 0.05 for both).</div></div><div><h3>Conclusions</h3><div>LSM by 2D SWE yields larger AUCs compared to µ_Diff obtained from DWI-based virtual elastography for various stages of liver fibrosis. LSM is superior to µ_Diff in predicting advanced fibrosis and cirrhosis.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101743"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD – a prospective interventional study","authors":"Adam Vašura ,&nbsp;Evžen Machytka ,&nbsp;Ondřej Urban ,&nbsp;Jitka Macháčková ,&nbsp;Lubomír Pavliska ,&nbsp;Zdeněk Berka ,&nbsp;Zdeněk Švagera ,&nbsp;Marek Bužga","doi":"10.1016/j.aohep.2024.101765","DOIUrl":"10.1016/j.aohep.2024.101765","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>With increases in obesity and metabolic syndrome because of lifestyle-related factors, the prevalence of non-alcoholic fatty liver disease (NAFLD) also is increasing worldwide. In a subset of patients with NAFLD, an inflammatory process arises in the steatotic liver, known as non-alcoholic steatohepatitis, that leads to liver fibrosis and liver cirrhosis. In selected patients with obesity, bariatric surgery, and bariatric endoscopy are important therapeutic options.</div></div><div><h3>Materials and Methods</h3><div>This prospective interventional pilot study was conducted to investigate two types of intragastric balloons (IGB). The IGBs were the Orbera and the Spatz3. Liver fibrosis changes were monitored non-invasively using point and 2D shear wave ultrasound elastography (SWE) and transient elastography that allowed for quantification of liver steatosis using the controlled attenuation parameter (CAP). Patients were followed for 12 months.</div></div><div><h3>Results</h3><div>Of 34 patients implanted with an IGB, 30 completed follow-up at month 12; results for one patient were excluded because of initiation of obesity pharmacotherapy. Fifteen patients received the Orbera IGB, and nineteen patients received the Spatz3 type. In month 12, total and excess weight loss was 7.88 % and 30.13 %. Elastography values decreased from baseline (3.88 kPa) to 3.61 kPa at month 12 (p 0.024). 2D SWE values decreased from baseline (5.42 kPa) to a value of 4.91 kPa at month twelve (p 0.135). Transient elastography values decreased from baseline (5.62 kPa) to a value of 4.17 kPa at month twelve (p 0.009).</div></div><div><h3>Conclusions</h3><div>Bariatric endoscopy in the form of IGB implantation leads to weight reduction and improvement of liver fibrosis and steatosis.</div></div><div><h3>ClinicalTrials.gov registration</h3><div>NCT04895943</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101765"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","authors":"Mi Zhou ,&nbsp;Jianyu Lv ,&nbsp;Xinli Chen ,&nbsp;Yujie Shi ,&nbsp;Guanqun Chao ,&nbsp;Shuo Zhang","doi":"10.1016/j.aohep.2025.101777","DOIUrl":"10.1016/j.aohep.2025.101777","url":null,"abstract":"<div><div>Non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), represents a significant and escalating global health challenge. Its prevalence is intricately linked to obesity, insulin resistance, and other components of the metabolic syndrome. As our comprehension of MASLD deepens, it has become evident that this condition extends beyond the liver, embodying a complex, multi-systemic disease with hepatic manifestations that mirror the broader metabolic landscape. This comprehensive review delves into the critical interplay between the gut-liver axis and oxidative stress, elucidating their pivotal roles in the etiology and progression of MASLD. Our analysis reveals several key findings: (1) Bile acid dysregulation can trigger oxidative stress through enhanced ROS production in hepatocytes and Kupffer cells, leading to mitochondrial dysfunction and lipid peroxidation; (2) Gut microbiota dysbiosis disrupts intestinal barrier function, allowing increased translocation of endotoxins like LPS, which activate inflammatory pathways through TLR4 signaling and promote oxidative stress via NADPH oxidase activation; (3) The redox-sensitive transcription factors NF-κB and Nrf2 serve as crucial mediators in the gut-liver axis, with NF-κB regulating inflammatory responses and Nrf2 orchestrating antioxidant defenses; (4) Oxidative stress-induced damage to intestinal barrier function creates a destructive feedback loop, further exacerbating liver inflammation and disease progression. These findings highlight the complex interrelationship between gut-liver axis dysfunction and oxidative stress in MASLD pathogenesis, suggesting potential therapeutic targets for disease management.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101777"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The rationale for the aggressive progression of MASLD in patients with type 2 diabetes","authors":"Valeria Michelle Fernández-Garibay,&nbsp;Norberto C. Chavez-Tapia","doi":"10.1016/j.aohep.2025.101778","DOIUrl":"10.1016/j.aohep.2025.101778","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101778"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019","authors":"Jacob Romano ,&nbsp;Jessica Burnside ,&nbsp;Giada Sebastiani ,&nbsp;Alnoor Ramji ,&nbsp;Keyur Patel ,&nbsp;Mark Swain ,&nbsp;Sahar Saeed","doi":"10.1016/j.aohep.2024.101757","DOIUrl":"10.1016/j.aohep.2024.101757","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Prevalence estimates are crucial for enhancing preparedness to prevent and manage chronic diseases. This is the first study to estimate the prevalence of hepatic steatosis and advanced fibrosis in Canada, leveraging a nationally representative survey and multiple validated non-invasive tests (NITs).</div></div><div><h3>Materials and Methods</h3><div>The Canadian Health Measures Survey (CHMS) is Canada's largest direct health measures survey, which collects data on sociodemographic, clinical factors, and blood chemistry. We determined steatosis using two NITs: the Hepatic Steatosis Index (HSI) and the NAFLD Ridge Score (NRS). The FIB-4 Index and NAFLD fibrosis score (NFS) were used to assess the risk of advanced fibrosis among adults with steatosis. Survey weights were incorporated to account for oversampling, survey nonresponse, and post-stratification.</div></div><div><h3>Results</h3><div>Between 2009 and 2019, 1365 children (55 % males, median age 13 (IQR: 10–15) and 4664 adults (51 % males, median age 45 (IQR: 34–62), 57 % reporting weekly alcohol consumption) were included in our study. The weighted steatosis prevalence ranged from 9 to 11 % among children to 38–48 % among adults based on the NRS and HSI, respectively. Between 86–87 % of adults with type 2 diabetes and 65–72 % with hypertension had evidence of steatosis. Overall, 1.2–2.4 % of adults with steatosis were at risk of advanced liver fibrosis.</div></div><div><h3>Conclusions</h3><div>We estimate between 1 in 3 and 1 in 2 adults have hepatic steatosis, and 195,000–406,200 are at high risk of advanced liver fibrosis in Canada. No routine screening guidelines for liver fibrosis exist in Canada, and most patients are unaware of their condition. Prevalence studies are essential for raising awareness and advocating for the inclusion of steatotic liver disease on national public health agendas.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101757"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142778855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}